Cullinan Therapeutics, Inc. (CGEM) Financials

CGEM Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 403.0 million 36.8 million
Dec. 31, 2025 448.4 million 39.6 million
Sept. 30, 2025 484.1 million 32.8 million
June 30, 2025 520.3 million 28.2 million

CGEM Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -46.0 million ?
Dec. 31, 2025 -38.1 million 7.3 million
Sept. 30, 2025 -36.9 million 9.5 million
June 30, 2025 -57.6 million 9.9 million

CGEM Net Income

No data available :(

CGEM Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 351.9 million 1.7 million -
Dec. 31, 2025 377.9 million 1.9 million 2.7 million
Sept. 30, 2025 332.6 million - 1.2 million
June 30, 2025 265.5 million - 1.5 million

CGEM Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 59.2 million
Dec. 31, 2025 59.2 million
Sept. 30, 2025 59.0 million
June 30, 2025 59.0 million

CGEM Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 42.1 million 11.6 million -
Dec. 31, 2025 11000 42.9 million 12.3 million -
Sept. 30, 2025 36.9 million 42.0 million 13.6 million -
June 30, 2025 - 61.0 million 14.8 million -

CGEM Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 79000
Dec. 31, 2025 - 79000
Sept. 30, 2025 - -
June 30, 2025 - 77000

CGEM

Price: $13.61

52 week price:
5.68
16.74

Earnings Per Share: -3.37 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 351200

Market Capitalization: 850.3 million

Links: